Geen aandoening: geneesmiddel wordt gebruikt om de effecten van een klinische interventie te verstevigen Boost memory effects of COMET
Conditions
Interventions
Participants select four mildly positive autobiographical memories. They
receive two intervention sessions. During each session, one memory will be
activated using COMET procedures and one memory wi
Sponsors
Universiteit Utrecht
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: The inclusion criteria match a previous study from our lab that involves yohimbine administration in healthy subjects (Protocol ID NL46836.041). - Age 18-30 - Written informed consent - Body Mass Index (BMI) between 17.5 and 26 - Passing the medical screening (heart rate and blood pressure, medical interview) - In females: the use of reliable contraceptives (birth control pills or a hormonal intrauterine device)
Exclusion criteria
Exclusion criteria: The exclusion criteria match a previous study from our lab that involves yohimbine administration in healthy subjects (Protocol ID NL46836.041). Assessed by physical exam: - High blood pressure: systolic blood pressure over 140 mmHg, diastolic over 90 mmHg - High heart rate: >90 beats per minute (bpm);Assessed by interview: - Inability to adequately read or speak Dutch - Known sensitivity to yohimbine - History of affective psychiatric disorders in the past 2 years - Lifetime history of neurological disease (attention/memory disorders, epilepsy, convulsions) - Current attention/memory problems - Lifetime history of any cardiovascular problem, coronary insufficiency, congestive heart failure, heart block, tachycardia, myocardial infarction, hypertension, chronic obstructive pulmonary disease, bronchial asthma, renal disorders, liver disorders, diabetes - Early age cardiovascular problems in first degree family members - Fainting easily (can be indicative of cardiovascular problems) - Chronic or frequent migraines - Use of any medication - Specified: use of anti-inflammatory painkillers in the past 3 dagen - Specified: use of anxiolytics or antacids in the past week - A score of * 26 on the Anxiety Sensitivity Index (ASI: Reiss, Peterson, Gursky, & McNally, 1986) (in order to eliminate individuals who might have difficulty with any temporary symptoms induced by the yohimbine manipulation). - Alcohol use of >2 units per day on one or more days during the past week - Any drug use during the past month - A score of *4 on the Fagerström Test for Nicotine Dependence (FTND: Heatherton, Kozlowski, Frecker, & Fagerstrom, 1991) (in order to eliminate individuals that are moderately or heavily dependent smokers).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Ease of recollection, specificity, vividness and positive affectivity of positive autobiographical memories at pre-test (baseline), post-test (after medication intake and COMET intervention) and 2-day follow-up measured with 100mm VASs. | — |
Secondary
| Measure | Time frame |
|---|---|
| Prior to and during the intervention, salivary *-amylase (sAA) levels, Skin Conductance Level (SCL) and Heart Rate (HR) are measured, as a manipulation check and in order to correlate noradrenaline/arousal levels with significant outcomes. | — |
Countries
Netherlands
Outcome results
None listed